Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Portfolio Pulse from Avi Kapoor
Landos Biopharma, Inc. (LABP) shares surged over 170% following acquisition news by AbbVie Inc. (ABBV). Other stocks also showed significant movement in Monday's mid-day session, with notable gainers including Next.e.GO N.V. (EGOX), Altamira Therapeutics Ltd. (CYTO), and MicroAlgo Inc. (MLGO), among others. Losers for the day included Sintx Technologies, Inc. (SINT), Akanda Corp. (AKAN), and Fisker Inc. (FSR), with declines attributed to various factors such as public offerings and terminated negotiations.
March 25, 2024 | 6:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie announced a definitive agreement to acquire Landos Biopharma, impacting its stock movement.
AbbVie's acquisition of LABP could be seen positively as a strategic expansion, potentially benefiting ABBV's stock in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 80
POSITIVE IMPACT
Landos Biopharma shares soared by 171.2% to $21.70 following acquisition news by AbbVie.
The sharp increase in LABP's stock price is directly attributed to the acquisition announcement by AbbVie, indicating a positive market response to the news.
CONFIDENCE 95
IMPORTANCE 100
RELEVANCE 100